Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Jacobson

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Blood|March 2, 2013
HIV gene therapy research advancesJeffrey M Jacobson
Current Opinion in HIV and AIDS|April 18, 2009
The rationale for immunosuppressive therapy for HIV infectionJeffrey M Jacobson
Current HIV/AIDS Reports|August 11, 2005
Immune-based therapies: an adjunct to antiretroviral treatmentJeffrey M Jacobson
The Journal of Infectious Diseases|June 7, 2022
Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in People With Human Immunodeficiency Virus: A Tale of Two PandemicsJeffrey M Jacobson
AIDS Reviews|December 15, 2018
Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are DevelopedJeffrey M Jacobson, Kamel Khalili
Current Opinion in HIV and AIDS|April 3, 2009
CCR5 monoclonal antibodies for HIV-1 therapyWilliam C Olson, Jeffrey M Jacobson
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infectionChristopher J Bruno, Jeffrey M Jacobson
Current Opinion in HIV and AIDS|April 4, 2017
Universal antiretroviral regimens: thinking beyond one-pill-once-a-dayJeffrey M Jacobson, Charles W Flexner
Current Opinion in HIV and AIDS|April 18, 2009
Treatment interruption as a tool to measure changes in immunologic response to HIV-1Michele A Kutzler, Jeffrey M Jacobson
Open Forum Infectious Diseases|February 21, 2024
Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD ScoresGeorge A Yendewa, Ana Khazan, Jeffrey M Jacobson
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Blood|March 2, 2013
HIV gene therapy research advancesJeffrey M Jacobson
Current Opinion in HIV and AIDS|April 18, 2009
The rationale for immunosuppressive therapy for HIV infectionJeffrey M Jacobson
Current HIV/AIDS Reports|August 11, 2005
Immune-based therapies: an adjunct to antiretroviral treatmentJeffrey M Jacobson
The Journal of Infectious Diseases|June 7, 2022
Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in People With Human Immunodeficiency Virus: A Tale of Two PandemicsJeffrey M Jacobson
AIDS Reviews|December 15, 2018
Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are DevelopedJeffrey M Jacobson, Kamel Khalili
Current Opinion in HIV and AIDS|April 3, 2009
CCR5 monoclonal antibodies for HIV-1 therapyWilliam C Olson, Jeffrey M Jacobson
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infectionChristopher J Bruno, Jeffrey M Jacobson
Current Opinion in HIV and AIDS|April 4, 2017
Universal antiretroviral regimens: thinking beyond one-pill-once-a-dayJeffrey M Jacobson, Charles W Flexner
Current Opinion in HIV and AIDS|April 18, 2009
Treatment interruption as a tool to measure changes in immunologic response to HIV-1Michele A Kutzler, Jeffrey M Jacobson
Open Forum Infectious Diseases|February 21, 2024
Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD ScoresGeorge A Yendewa, Ana Khazan, Jeffrey M Jacobson
Pageof 17